Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFINE: Ranibizumab in Chinese DME
NCT02259088Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2014
- Primary completion
- Jan 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in diabetic macular edema (DME), sponsored by Novartis. Started Nov 2014; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02259088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259088.